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Introduction 
Many neoplasms in dermatology are managed with 
the innovative surgical technique of Mohs 
micrographic surgery (MMS). This precise technique 
involves progressive removal of the target lesion in 
layers that are then processed as horizontal sections 
and examined under microscopy for tumor 
clearance by the Mohs surgeon before the defect is 
repaired. The introduction of fresh frozen tissue, in 
lieu of in vivo tissue fixation, further accelerated the 
practice of MMS as it became standard of care for 
treating basal cell and squamous cell carcinomas 
with high-risk microscopic features or in cosmetically 
sensitive locations. Mohs micrographic surgery can 
treat a variety of rare non-melanocytic cutaneous 
malignancies (with a contiguous growth pattern) for 
which achieving remission and the optimal aesthetic 
result after surgery was previously difficult. 
 
Discussion 
Dermatofibrosarcoma protuberans is a spindle cell, 
locally aggressive tumor with a predilection for the 
trunk and proximal extremities. Owing to their 
contiguous but asymmetric growth pattern, 
dermatofibrosarcoma protuberans tumors can have 
a high rate of margin positivity and recurrence 
following standard excision [1]. Margins as high as 
10cm were used to excise dermatofibrosarcoma 
protuberans, though standard margins were 
generally less than 5cm [1]. As it can gradually track 
microscopic tumor extension, the MMS technique 
became the treatment of choice for 
dermatofibrosarcoma protuberans. This technique is 
further optimized with CD34 immunohistochemical 
staining on frozen sections to help assess tumor 
margins. As a result, MMS for dermatofibrosarcoma 
protuberans, particularly with successful 
immunohistochemical staining, can minimize the 
chance of tumor recurrence as well as morbidity 
from re-excision.  
Atypical fibroxanthomas are pleomorphic spindle 
cell neoplasms frequently found on the head and 
neck, with predominance in males [2]. They appear 
as a nonspecific pink or red papule or nodule on sun-
damaged skin. Atypical fibroxanthomas are 
considered to be part of the spectrum of 
Abstract 
Mohs micrographic surgery (MMS) is a breakthrough 
surgical technique that has changed the 
management of neoplasms in dermatology. Through 
continued practice and evolution, MMS now can 
successfully treat a variety of rare non-melanocytic 
cutaneous malignancies for which achieving 
remission and the optimal aesthetic result after 
surgery was previously challenging. Mohs 
micrographic surgery has utility for conditions 
besides melanoma. Herein, we discuss this versatility 
of Mohs micrographic surgery. Specifically, Mohs 
micrographic surgery can be successfully used for 
cases such as dermatofibrosarcoma protuberans, 
atypical fibroxanthomas, extramammary Paget 
disease, Merkel cell carcinoma, sebaceous carcinoma, 
and microcystic adnexal carcinoma. 
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pleomorphic dermal sarcomas. Surgery remains the 
mainstay of management and complete margin 
control is critical [3]. To date, several retrospective 
studies have found a lower local recurrence rate with 
MMS compared to standard excision, with the added 
benefit of tissue preservation. Thus, MMS is an 
excellent option for atypical fibroxanthomas, 
especially as they tend to arise in cosmetically 
sensitive regions. 
Extramammary Paget disease is a rare and slow-
growing epithelial tumor with a predilection for the 
genitalia or less commonly, axilla. Its diagnosis is 
often delayed because it mimics numerous benign 
entities, including eczema, psoriasis, seborrheic 
dermatitis, contact dermatitis, or cutaneous fungal 
infections. In addition, the margins of 
extramammary Paget disease can be multifocal and 
difficult to distinguish both microscopically and 
clinically, resulting in a high recurrence rate 
following excision [4]. Because standard surgical 
excision can result in significant morbidity and 
deformity of the genitourinary region, the MMS 
technique became increasingly utilized. Evidence 
suggests that MMS with an average of 2.5cm margins 
led to decreased recurrence rates of primary as well 
recurrent extramammary Paget disease compared to 
standard excision with 5cm margins [4]. As it is tissue 
sparing, MMS furthermore allows preservation of 
important genitourinary anatomic structures such as 
the vulva, urethra, and scrotum. 
Merkel cell carcinoma is another rare but fast-
growing malignancy of neuroendocrine origin that 
often appears on the head and neck. Risk factors for 
Merkel cell carcinoma include sunlight exposure, 
immunosuppression, and exposure to 
polyomaviruses [5]. Although excision is standard of 
care for the management of Merkel cell carcinoma, a 
recent review of all stage I and II Merkel cell 
carcinoma cases in the National Cancer Database 
found that MMS was equally as effective as wide local 
excision. This data suggests MMS as a viable option 
for Merkel cell carcinoma in functionally sensitive 
areas without sacrificing survival rates [5]. 
Sebaceous carcinoma, a rare epithelial malignancy 
most commonly from the eyelid Meibomian glands, 
is an aggressive tumor. Like extramammary Paget 
disease, early diagnosis can be difficult, as its 
periocular predilection can clinically mimic a benign 
chalazion or chronic blepharoconjunctivitis. Notably, 
70% of sebaceous carcinomas occur on the head or 
neck, for which a tissue preserving surgical 
technique is functionally essential. In addition, MMS 
for sebaceous carcinoma had significantly lower 
rates of local recurrence (11%) and regional 
metastases (6-8%) when compared to excisional 
removal (37% and 28%, respectively), [6]. Thus, MMS 
is the first-line treatment for sebaceous carcinoma as 
a result of its improved tissue conservation and 
better outcomes.  
Microcystic adnexal carcinoma is an epithelial tumor 
of follicular and glandular differentiation with 
potential for deep infiltration and perineural 
invasion. It often appears as a smooth-surfaced, non-
ulcerated, flesh-colored-to-yellowish asymptomatic 
nodule, papule, plaque, or cystic lesion. Because 
microcystic adnexal carcinoma also favors the head 
and neck, with a predilection for central face, 
increasing interest has been placed on MMS for 
tumor removal. As the Mohs technique allows 
systematic margin control, the rate of tumor 
clearance is optimized. This has been demonstrated 
in a study where 30% of patients treated initially with 
wide local excision required at least one additional 
procedure, either re-excision or subsequent MMS, 
owing to pathologic confirmation of positive 
margins on the excision specimen. In contrast, none 
of the MMS surgery patients required further 
procedures [7]. These findings suggest that MMS can 
offer a higher likelihood of tumor clearance on a 
single visit for management of microcystic adnexal 
carcinomas. 
 
Conclusion 
Today, MMS has utility for non-melanocytic skin 
cancers beyond basal cell and squamous cell 
carcinomas. Its effective removal of more rare 
neoplasms, including those of fibrohistiocytic, 
neuroendocrine, and adnexal origins described 
above, makes dermatology surgeons an essential 
part of the team approach in the management of 
cutaneous malignancies that were previously 
referred out to surgery subspecialty teams. 
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